Weight loss startup Calibrate raises $29M as part of private equity restructuring
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.)
Calibrate, the weight loss startup that rose in popularity with the rise of GLP-1 medications only to struggle to get patients access to those medications — leading to patient complaints and refunds — has raised $29 million as part of its restructuring under a private equity investor.
The new funding, which was disclosed in a Wednesday filing with the Securities and Exchange Commission, comes as Calibrate goes through major changes to its business. Insider in October reported that the private equity firm Madryn Asset Management is buying Calibrate. Calibrate previously told Modern Healthcare it was receiving capital from Madryn and existing investors.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.